China Ribonucleic Acid II (RNAII) for Injection Market Investigation Report 2015

Aug 17, 2015, 07:10 ET from Research and Markets

DUBLIN, Aug. 17, 2015 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Investigation Report on China's ribonucleic acid II (RNAII) for Injection, 2010-2019" report to their offering.

RNAII for injection, one kind of immunomodulator, can improve body immunity and inhibit tumor by causing vacuolar degeneration and colliquative necrosis in tumor cells as well as generating large amounts of hyperplastic fibroblasts, macrophages, lymphocytes or even connective tissue to substitute tumor tissue. And it is used for the adjuvant treatment of pancreatic cancer, liver cancer, stomach cancer, breast cancer, soft tissue sarcoma and other cancers especially hepatitis B. RNAII for injection can also be used for the treatment of various diseases caused by low immune function.

According to the market survey, RNAII for injection develops fast in China with sales value rising from less than CNY 60 million in 2005 to about CNY 500 million in 2014 and CAGR during this period reaching 80%.

With the lifestyle changes brought about by economic development as well as the serious environmental pollution, the incidence of cancer keeps increasing with the number of new cases exceeding 3 million each year in China. Meanwhile, there are over 90 million hepatitis B patients in China too. Therefore, the market size of RNAII for injection is expected to keep growing in the next few years in China.

Key Topics Covered:

1 Related Concepts of RNAII for Injection

2 Market Profile of RNAII for Injection in China

3 Survey on Sales Status of RNAII for Injection in China, 2010-2014

4 Survey on Market Share of Major Manufacturers of RNAII for Injection in China, 2010-2014

5 Survey on Dosage Forms of RNAII for Injection in China, 2010-2014

6 Reference Price of RNAII for Injection in Chinese Hospitals in 2014

7 Major Manufacturers of RNAII for Injection in Chinese Market, 2010-2014

8 Market Outlook of RNAII for Injection in China, 2015-2019

Companies Mentioned

- Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd
- Nanjing Xinbai Pharmaceutical Co., Ltd
- Xinxiang Dongsheng Pharmaceutical Co., Ltd

For more information visit

Media Contact: Laura Wood , +353-1-481-1716,

SOURCE Research and Markets